Related Experiment Video
Updated: Dec 25, 2025
06:03
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
18.0K
ROS1-rearranged lung adenocarcinoma with peritoneal carcinomatosis on initial presentation
Vera Kazakova1, Sylvia V Alarcon Velasco2, Aleksandr Perepletchikov3
1Department of Medicine, St Elizabeth's Medical Center, Boston, Massachusetts, USA vera.kazakova@steward.org.
BMJ Case Reports
|March 29, 2020
Summary
Peritoneal carcinomatosis (PC) is rare in lung cancer. This case highlights ROS1-rearranged lung adenocarcinoma presenting as PC, responding well to crizotinib targeted therapy.
Area of Science:
- Oncology
- Genetics
- Gastroenterology
Background:
- Peritoneal carcinomatosis (PC) is a rare but serious complication of lung cancer.
- Predisposing factors for peritoneal spread remain poorly understood.
- The role of specific oncogene mutations, such as ROS1, in PC development is unclear.
Observation:
- A 56-year-old male presented with new-onset ascites, indicative of PC.
- The patient was diagnosed with ROS1-rearranged lung adenocarcinoma.
- No primary tumor was initially identified.
Findings:
- The patient's PC was attributed to ROS1-rearranged lung adenocarcinoma.
- Targeted therapy with crizotinib demonstrated significant efficacy.
- The patient achieved 6 months of disease progression-free survival.
Implications:
- This case suggests ROS1 rearrangements may contribute to peritoneal carcinomatosis in lung cancer.
- Targeted therapy with crizotinib can be an effective treatment option for such cases.
- Further research is needed to elucidate the mechanisms of peritoneal spread in ROS1-positive lung cancer.
